ICL deputy CEO reports stock option holdings

ICL Group Ltd. Deputy Chief Executive Officer Geva Harel Lilach reported existing holdings of stock options to buy Ordinary Shares.

Accepted by SEC EDGAR 03/30/2026 - 06:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ICL Group Ltd. Deputy Chief Executive Officer Geva Harel Lilach reported existing holdings of stock options to buy Ordinary Shares. The Form 3 lists three option grants with exercise prices in U.S. dollars, converted from New Israeli Shekels using Bank of Israel exchange rates.

One option grant covers 649,180 underlying shares at an exercise price of $9.39 per share, is fully vested and exercisable, and expires on February 8, 2027. Additional grants cover 984,095 underlying shares at $5.87 per share expiring April 4, 2029, and 416,667 underlying shares at $5.91 per share expiring December 7, 2030, each vesting in three equal annual installments from their respective grant dates. The options are held by a Trustee in the name of the reporting person.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Geva Harel Lilach

Role Deputy Chief Executive Officer

Type	Security	Shares	Price	Value
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--

Holdings: Stock Options (Right to Buy) — 2,049,942 contracts (Direct)

Footnotes (7)

1. F1. The stock options are fully vested and exercisable.
2. F2. The stock options vest in three equal annual installments from the April 4, 2024, grant date.
3. F3. The stock options vest in three equal annual installments from the December 7, 2025, grant date.
4. F4. Represents an exercise price of NIS 29.57, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
5. F5. The options are held by a Trustee in the name of the Reporting Person.
6. F6. Represents an exercise price of NIS 18.47, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
7. F7. Represents an exercise price of NIS 18.60, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

Key Figures

Underlying shares (grant 1): 649,180 shares Exercise price (grant 1): $9.39 per share Underlying shares (grant 2): 984,095 shares +3 more

6 metrics

Underlying shares (grant 1) 649,180 shares Stock options at $9.39 exercise price, expiring February 8, 2027

Exercise price (grant 1) $9.39 per share Converted from NIS 29.57 using Bank of Israel rate on March 27, 2026

Underlying shares (grant 2) 984,095 shares Stock options at $5.87 exercise price, expiring April 4, 2029

Underlying shares (grant 3) 416,667 shares Stock options at $5.91 exercise price, expiring December 7, 2030

Vesting schedule (grant 2) 3 equal annual installments From April 4, 2024 grant date

Vesting schedule (grant 3) 3 equal annual installments From December 7, 2025 grant date

Key Terms

Stock Options (Right to Buy), Ordinary Shares, exercise price, vest in three equal annual installments, +1 more

5 terms

Stock Options (Right to Buy) financial

"security_title: "Stock Options (Right to Buy)" for each entry"

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares" for all option grants"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"Represents an exercise price of NIS 29.57, converted to U.S. dollars"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in three equal annual installments financial

"The stock options vest in three equal annual installments from the grant date"

Trustee financial

"The options are held by a Trustee in the name of the Reporting Person."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ICL (ICL) Form 3 filing by Geva Harel Lilach report?

The Form 3 reports Deputy CEO Geva Harel Lilach’s existing stock option holdings in ICL Group Ltd. It details three option grants over Ordinary Shares, including underlying share amounts, exercise prices in U.S. dollars, vesting schedules, and expiration dates, all held directly through a Trustee.

How many ICL stock options does the deputy CEO have and at what exercise prices?

The deputy CEO holds options over 649,180 underlying shares at $9.39, 984,095 underlying shares at $5.87, and 416,667 underlying shares at $5.91. These exercise prices are converted from New Israeli Shekels using the Bank of Israel representative exchange rate as of March 27, 2026.

What are the vesting terms of the ICL stock options reported in this Form 3?

One block of options over 649,180 shares is fully vested and exercisable. Options over 984,095 shares vest in three equal annual installments from the April 4, 2024 grant date, while options over 416,667 shares vest in three equal annual installments from the December 7, 2025 grant date.

When do the ICL deputy CEO’s reported stock options expire?

The reported ICL options expire on three different dates: one grant over 649,180 shares expires on February 8, 2027; another over 984,095 shares expires on April 4, 2029; and the final grant over 416,667 shares expires on December 7, 2030, if not exercised earlier.

Does the ICL Form 3 show any recent buying or selling of shares by the deputy CEO?

The Form 3 does not show open-market buying or selling; it lists existing stock option holdings. The entries are categorized as holdings of stock options (rights to buy Ordinary Shares), with no reported buy or sell transaction codes or share amounts changing hands in the disclosure.

How are the ICL deputy CEO’s options held according to the Form 3 footnotes?

The footnotes explain that the options are held by a Trustee in the name of the reporting person. This means a Trustee entity formally holds the options on behalf of Deputy CEO Geva Harel Lilach, while the filing still reflects them as direct beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Geva Harel Lilach

(Last) (First) (Middle)

C/O ICL GROUP LTD.

MILLENNIUM TOWER, 23 ARENHA ST.

(Street)

TEL AVIV 6120201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ICL Group Ltd. [ ICL ]

3a. Foreign Trading Symbol
[ICL]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Deputy Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	(1)	02/08/2027	Ordinary Shares	649,180	$9.39(4)	D(5)
Stock Options (Right to Buy)	(2)	04/04/2029	Ordinary Shares	984,095	$5.87(6)	D(5)
Stock Options (Right to Buy)	(3)	12/07/2030	Ordinary Shares	416,667	$5.91(7)	D(5)

Explanation of Responses:

1. The stock options are fully vested and exercisable.

2. The stock options vest in three equal annual installments from the April 4, 2024, grant date.

3. The stock options vest in three equal annual installments from the December 7, 2025, grant date.

4. Represents an exercise price of NIS 29.57, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

5. The options are held by a Trustee in the name of the Reporting Person.

6. Represents an exercise price of NIS 18.47, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

7. Represents an exercise price of NIS 18.60, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

	/s/ Geva Harel Lilach	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)